In the last trading session, 14.1 million shares of the Channel Therapeutics Corporation (AMEX:CHRO) were traded. Most recently the company’s share price was $1.90, and it changed around $0.94 or 97.92% from the last close, which brings the market valuation of the company to $11.46M. CHRO currently trades at a discount to its 52-week high of $6.00, offering almost -215.79% off that amount. The share price’s 52-week low was $0.45, which indicates that the current value has risen by an impressive 76.32% since then. We note from Channel Therapeutics Corporation’s average daily trading volume that its 10-day average is 1.55 million shares, with the 3-month average coming to 143.88K.

Channel Therapeutics Corporation stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended CHRO as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Channel Therapeutics Corporation is expected to report earnings per share of -0.21 for the current quarter.

Channel Therapeutics Corporation (AMEX:CHRO) trade information

Instantly CHRO has showed a green trend with a performance of 97.92% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 2.4500 on recent trading dayincreased the stock’s daily price by 22.45%. The company’s shares are currently up 196.41% year-to-date, but still up 110.51% over the last five days. On the other hand, Channel Therapeutics Corporation (AMEX:CHRO) is 221.43% up in the 30-day period. We can see from the shorts that 58233.0 shares have been sold at a short interest cover period of 0.26 day(s).

CHRO Dividends

Channel Therapeutics Corporation’s next quarterly earnings report is expected to be released in February.

The former held 5.01 shares worth $9520.0, making up 0.08% of all outstanding shares.